Lisanti Capital Growth LLC Invests $1.59 Million in Guardant Health, Inc. $GH

Lisanti Capital Growth LLC bought a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 10,610 shares of the company’s stock, valued at approximately $1,592,000.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after purchasing an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Guardant Health by 14.9% during the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after acquiring an additional 435,232 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after acquiring an additional 277,001 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in Guardant Health by 3.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after acquiring an additional 72,162 shares during the period. 92.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Citigroup boosted their price objective on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Sanford C. Bernstein raised their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, July 2nd. BTIG Research lifted their target price on Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Wolfe Research assumed coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price target on the stock. Finally, Barclays increased their price target on shares of Guardant Health from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $183.78.

Guardant Health Price Performance

Guardant Health stock opened at $163.34 on Thursday. The firm has a market capitalization of $21.92 billion, a P/E ratio of -46.80 and a beta of 1.60. Guardant Health, Inc. has a one year low of $53.40 and a one year high of $176.58. The business has a fifty day moving average price of $152.39 and a 200-day moving average price of $117.95.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. The business’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.44) earnings per share. Sell-side analysts expect that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other news, CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. This trade represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ian T. Clark sold 14,180 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the transaction, the director directly owned 2,975 shares of the company’s stock, valued at approximately $472,787. This represents a 82.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 546,224 shares of company stock worth $80,435,493. 5.60% of the stock is owned by corporate insiders.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.